CN104876851A - 一类含吲哚-3羧酸骨架的哌嗪类衍生物的制备方法及在抗癌药物中的应用 - Google Patents
一类含吲哚-3羧酸骨架的哌嗪类衍生物的制备方法及在抗癌药物中的应用 Download PDFInfo
- Publication number
- CN104876851A CN104876851A CN201510252697.6A CN201510252697A CN104876851A CN 104876851 A CN104876851 A CN 104876851A CN 201510252697 A CN201510252697 A CN 201510252697A CN 104876851 A CN104876851 A CN 104876851A
- Authority
- CN
- China
- Prior art keywords
- arh
- preparation
- compound
- reaction
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000004885 piperazines Chemical class 0.000 title claims abstract description 22
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 5
- 238000002360 preparation method Methods 0.000 title abstract description 58
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 64
- 238000006243 chemical reaction Methods 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 239000000543 intermediate Substances 0.000 claims description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 229940125782 compound 2 Drugs 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 239000012044 organic layer Substances 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 3
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 229940126214 compound 3 Drugs 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 150000005826 halohydrocarbons Chemical class 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 2
- 239000007806 chemical reaction intermediate Substances 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 27
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 24
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 16
- 229940124530 sulfonamide Drugs 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 8
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 8
- 150000002475 indoles Chemical class 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- -1 3-substituted indole Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 4
- YGFNUUCMQMZGJV-UHFFFAOYSA-N 4-amino-n-nitrobenzenesulfonamide Chemical compound NC1=CC=C(S(=O)(=O)N[N+]([O-])=O)C=C1 YGFNUUCMQMZGJV-UHFFFAOYSA-N 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KVYUUZYMGPMFBE-UHFFFAOYSA-N S(=O)(C1=CC=C(C=C1)N)(=O)N.[Cl] Chemical compound S(=O)(C1=CC=C(C=C1)N)(=O)N.[Cl] KVYUUZYMGPMFBE-UHFFFAOYSA-N 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 229940125846 compound 25 Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 0 CC[n]1c2ccccc2c(*N(CC2)CCN2S(c(cc2)ccc2Br)(=O)=O)c1 Chemical compound CC[n]1c2ccccc2c(*N(CC2)CCN2S(c(cc2)ccc2Br)(=O)=O)c1 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Abstract
本发明公开了一类含吲哚-3羧酸骨架的哌嗪类衍生物,相关制备方法以及在制备抗肿瘤药物中的应用,其制备方法征是有如下通式:
Description
技术领域
本发明涉及药物化学技术领域,是一类含吲哚-3羧酸骨架的哌嗪类衍生物的制备方法及在抗癌药物中的应用。
背景技术
吲哚在生物医学、材料科学、农业化学等研究领域中有着广泛的应用。目前,在已发现的3000多种天然吲哚衍生物中,有40几种是治疗型药物,其中,绝大部分都是3-取代吲哚衍生物。3-吲哚乙酸是一种植物生长调节激素,合成的3-吲哚乙酸衍生物-消炎痛,已用于治疗风湿性关节炎。与其结构相似的褪黑激素(N-乙酰-5-甲氧基色胺)可控制生理功能的昼夜节律。吲哚及其衍生物的研究虽已有一百多年的历史,但对其研究的兴趣日益剧增,特别是随着生命科学的发展以及用于调控生理病理的内源性小分子药物的需求,该领域的研究又成为人们关注的热点之一。
哌嗪是许多药物分子的关键结构,可用于抗真菌、抗病毒或胆固醇酯转移蛋白抑制剂,特别是某些取代哌嗪化合物还具有抗癌活性.但是,目前所有临床使用的化疗抗癌药物都具有毒副作用,即由于药物对肿瘤组织缺乏定位作用而在杀死癌细胞的同时对正常细胞也构成极大损害.为了降低这种毒副作用,通常需减少药物的剂量,但剂量的减少常使疗效降低.因此,合成出新的能富集于肿瘤组织的抗癌药物是非常有意义的。
基于此,本发明将哌嗪构筑于吲哚-3羧酸分子中,设计合成了一系列一类含吲哚-3羧酸骨架的哌嗪类衍生物,期望具有更好的生物活性、更高的选择性、更低的毒性。
发明内容
发明目的:
1.提供一类含吲哚-3羧酸骨架的哌嗪类衍生物,以解决现有技术存在的问题。
2.提供上述衍生物的制备方法。
3.提供一种上述衍生物在制备抗肿瘤药物中的应用。
技术方案:一类含吲哚-3羧酸骨架的哌嗪类衍生物,其具有如式下所示的结构,
其中,所述R1选自烷基、芳香基等;R2选自烷基、芳香基、卤素等。
一类含吲哚-3羧酸骨架的哌嗪类衍生物的合成过程,它有如下通式:
所述R1选自烷基;R2选自烷基和卤素。
上述的含吲哚-3羧酸骨架的哌嗪类衍生物的合成包括下列步骤:
步骤1:在0±5℃搅拌作用下,将化合物1溶于无水甲醇中,并滴加SOCl2,转移至80±10℃,搅拌反应,制得中间体化合物2;各物质的摩尔比为I∶SOCl3=1∶2~5,反应时间为6±3h;进一步优选的摩尔比为1∶4,优选的温度分别为0℃、80℃,优选的反应时间8h;
步骤2:在0±5℃搅拌作用下,依次向反应容器中加入溶有中间体化合物2的THF溶液,然后缓慢滴加溶有少量NaH的THF溶液,移至室温后慢慢滴加卤代烃。继续搅拌反应12h,减压除去THF,乙酸乙酯萃取,有机层依次用饱和的食盐水和蒸馏水洗涤,无水硫酸镁干燥,减压除去溶剂得粗产物3.
步骤3:在0±5℃搅拌作用下,依次向反应容器中加入化合物3、氢氧化钾溶液,THF,甲醇,水,70±5℃搅拌;反应结束后酸化得中间体4。
步骤4:在搅拌作用下,依次向反应容器中加入磺酰氯、哌嗪、DMAP和二氯甲烷,室温反应中间体6e-6j。
步骤5:在0±5℃搅拌作用下,依次向反应容器中加入4a-4d、6e-6j、DMAP、HOBT、无水二氯甲烷和EDC.HCl,转移至25±10℃继续搅拌反应,提取得到目标化合物7-31。
本制备方法有效整合了吲哚3酸酸,哌嗪和磺胺骨架这些药效基团,实验可重复性强,稳定性好,实验反应所需条件较简单,且实验环境温和,产率较好,可在较小投入情况下进行大量生产。
有益效果:本发明对***细胞(HeLa)有明显的抑制作用。因此,本发明公开的这类含吲哚-3羧酸骨架的哌嗪类衍生物具有更好的生物活性、更高的选择性和更低的毒性。
具体实施方式
本发明的一个详细实施方式如下:
步骤1:在0℃搅拌作用下,将化合物1溶于无水甲醇中,并滴加SOCl2,转移至80℃,搅拌反应,减压除去溶剂,用乙酸乙酯萃取,有机层依次用饱和食盐水和蒸馏水洗涤,无水硫酸镁干燥,加压除去溶剂制得中间体化合物2。
步骤2:在0℃搅拌作用下,依次向反应容器中加入溶有中间体化合物2的THF溶液,然后缓慢滴加溶有少量NaH的THF溶液,移至室温后慢慢滴加卤代烃。继续搅拌反应12h,减压除去THF,乙酸乙酯萃取,有机层依次用饱和的食盐水和蒸馏水洗涤,无水硫酸镁干燥,减压除去溶剂得粗产物3.
步骤3:在0℃搅拌作用下,依次向反应容器中加入化合物3、氢氧化钾溶液,体积比为1∶1∶1的THF、甲醇和水的混合液,70℃搅拌;反应结束后酸化得中间体4。
步骤4:在搅拌作用下,依次向反应容器中加入磺酰氯、哌嗪、DMAP和二氯甲烷,反应液依次用饱和KHSO4水溶液、饱和Na2CO3、饱和食盐水洗涤,无水硫酸镁干燥,减压蒸馏,将得到的固体粗产物溶于无水乙醇重结晶得中间体6e-6j。
步骤5:在55℃搅拌作用下,依次向反应容器中加入中间物4、HOBt和无水二氯甲烷、EDC,30±5min后,再加入中间体6。继续搅拌,TLC跟踪反应,8±3h后,反应液依次用饱和KHSO4水溶液、饱和Na2CO3、饱和食盐水洗涤,无水硫酸镁干燥,减压蒸馏,将得到的固体粗产物溶于无水乙醇重结晶得到目标化合物(7-31)。
实施例一:1-乙基-吲哚-3-甲酰-(4-磺胺)哌嗪(化合物7)的制备
在55℃搅拌作用下,依次向反应容器中加入中间物4、HOBt和无水二氯甲烷、EDC,30±5min后,再加入中间体6。继续搅拌,TLC跟踪反应,8±3h后,反应液依次用饱和KHSO4水溶液、饱和Na2CO3、饱和食盐水洗涤,减压蒸馏,将得到的固体粗产物溶于无水乙醇重结晶得到目标化合物。
白色固体,产率63%;1H NMR(DMSO-d6,300MHz)δ:7.75(t,J=3.00Hz,3H,ArH,CHN),7.71(s,1H,ArH),7.68(t,J=5.60Hz,2H,ArH),7.63(t,J=5.40Hz,1H,ArH),7.47(d,J=6.20Hz,1H,ArH),7.21(t,J=5.70Hz,1H,ArH),7.11(t,J=5.60Hz,1H,ArH),3.79(s,3H,CH3),3.71(t,J=3.70Hz,4H,CH2),2.96(t,J=3.70Hz,4H,CH2).ESI-MS:m/z 383.5(M+).Anal.Calcd for C19H15N5O9S:C,H,N;
实施例二:1-甲基-吲哚-3-甲酰-(4-磺胺)哌嗪(化合物8)的制备
制备方法参考实施例一。白色固体,产率67%;1H NMR(DMSO-d6,300MHz)δ:7.88(dd,J=5.00Hz,J=1.50Hz,2H,ArH,CHN),7.72(s,1H,ArH),7.69(t,J=1.60Hz,1H,ArH),7.67(t,J=1.70Hz,1H,ArH),7.64(d,J=5.90Hz,1H,ArH),7.48(d,J=6.20Hz,1H,ArH),7.21(t,J=5.80Hz,1H,ArH),7.11(t,J=5.70Hz,1H,ArH),3.80(s,3H,CH3),3.71(t,J=3.60Hz,4H,CH2),2.98(t,J=3.60Hz,4H,CH2).ESI-MS:m/z 464.3(M+).
实施例三:1-苄基-吲哚-3-甲酰-(4-对溴磺胺)哌嗪(化合物9)的制备
制备方法参考实施例一。白色固体,产率62%;1H NMR(DMSO-d6,300MHz)δ:7.78~7.69(m,5H,ArH,CHN),7.64(d,J=5.90Hz,1H,ArH),7.48(d,J=6.10Hz,1H,ArH),7.21(t,J=5.70Hz,1H,ArH),7.12(t,J=5.80Hz,1H,ArH),3.79(s,3H,CH3),3.71(t,J=3.60Hz,4H,CH2),2.99(t,J=3.60Hz,4H,CH2).ESI-MS:m/z417.9(M+).
实施例四:1-乙基-吲哚-3-甲酰-(4-对溴磺胺)哌嗪(化合物10)的制备
制备方法参考实施例一。白色固体,产率59%;1H NMR(DMSO-d6,300MHz)δ:7.71(s,1H,ArH),7.63(d,J=6.10Hz,3H,ArH,CHN),7.46(d,J=5.00Hz,3H,ArH),7.21(t,J=5.60Hz,1H,ArH),7.11(t,J=5.60Hz,1H,ArH),3.79(s,3H,CH3),3.71(t,J=3.80Hz,4H,CH2),2.93(t,J=3.60Hz,4H,CH2),2.41(s,3H,CH3).ESI-MS:m/z 397.5(M+).
实施例五:1-丙基-吲哚-3-甲酰-(4-对甲基磺胺)哌嗪(化合物11)的制备
制备方法参考实施例一。黄色固体,产率63%;1H NMR(DMSO-d6,300MHz)δ:8.45(d,J=6.50Hz,2H,ArH,CHN),8.02(d,J=6.50Hz,2H,ArH),7.70(s,1H,ArH),7.64(d,J=5.90Hz,1H,ArH),7.48(d,J=6.10Hz,1H,ArH),7.21(t,J=5.70Hz,1H,ArH),7.11(t,J=5.60Hz,1H,ArH),3.79(s,3H,CH3),3.73(t,J=3.50Hz,4H,CH2),3.06(t,J=3.30Hz,4H,CH2),1.36(t,J=5.30Hz,3H,CH3).ESI-MS:m/z428.5(M+).
实施例六:1-甲基-吲哚-3-甲酰-(4-对溴磺胺)哌嗪(化合物12)的制备
制备方法参考实施例一。白色固体,产率65%;1H NMR(DMSO-d6,300MHz)δ:7.81(s,1H,ArH),7.71(d,J=5.90Hz,1H,CHN),7.49(d,J=6.10Hz,1H,ArH),7.32(d,J=5.70Hz,2H,ArH),7.22(t,J=5.50Hz,1H,ArH),7.14(t,J=5.60Hz,1H,ArH),4.13~4.06(m,2H,CH),3.82(s,3H,CH3),3.68(t,J=3.40Hz,4H,CH2),3.13(t,J=3.40Hz,4H,CH2),2.98~2.91(m,1H,CH),1.22(d,J=5.10Hz,18H,CH3).ESI-MS:m/z 509.7(M+).
实施例七:1-丙基-吲哚-3-甲酰-(4-磺胺)哌嗪(化合物13)的制备
制备方法参考实施例一。黄色固体,产率63%;1H NMR(DMSO-d6,300MHz)δ:7.77~7.62(m,7H,ArH,CHN),7.48(d,J=5.40Hz,1H,ArH),7.21(t,J=5.70Hz,1H,ArH),7.11(t,J=5.55Hz,1H,ArH),3.79(s,3H,CH3),3.72(t,J=3.75Hz,4H,CH2),2.96(t,J=6.60Hz,4H,CH2),2.51(s,2H,CH2).ESI-MS:m/z 397.5(M+).
实施例八:1-苄基-吲哚-3-甲酰-(4-对甲基磺胺)哌嗪(化合物14)的制备
制备方法参考实施例一。白色固体,产率56%;1H NMR(DMSO-d6,300MHz)δ:7.61(d,J=6.20Hz,2H,ArH,CHN),7.46(d,J=6.10Hz,2H,ArH,),7.28(t,J=5.40Hz,2H,ArH),7.22(t,J=4.50Hz,3H,ArH),7.64(d,J=5.90Hz,1H,ArH),7.48(d,J=6.20Hz,1H,ArH),7.21(t,J=5.80Hz,1H,ArH),3.44(s,2H,CH2),2.84(s,4H,CH2),2.42(s,4H,CH2).ESI-MS:m/z 476.4(M+).
实施例九:1-乙基-吲哚-3-甲酰-(4-对甲基磺胺)哌嗪(化合物15)的制备
制备方法参考实施例一。白色固体,产率64%;1H NMR(DMSO-d6,300MHz)δ:7.78~7.72(m,5H,ArH,CHN),7.64(d,J=6.00Hz,1H,ArH),7.53(d,J=6.50Hz,1H,ArH),7.19(t,J=5.70Hz,1H,ArH),7.11(t,J=5.70Hz,1H,ArH),4.22(q,J=5.40Hz,2H,CH2),3.72(t,J=3.50Hz,4H,CH2),2.99(t,J=3.50Hz,4H,CH2),1.36(t,J=5.40Hz,3H,CH3).ESI-MS:m/z 431.9(M+).
实施例十:1-苄基-吲哚-3-甲酰-(4-磺胺)哌嗪(化合物16)的制备
制备方法参考实施例一。白色固体,产率65%;1H NMR(DMSO-d6,300MHz)δ:7.76(s,1H,ArH),7.63(d,J=6.00Hz,3H,ArH,CHN),7.52(d,J=6.20Hz,1H,ArH),7.46(d,J=6.00Hz,2H,ArH),7.19(t,J=5.70Hz,1H,ArH),7.10(t,J=5.70Hz,1H,ArH),4.20(q,J=5.50Hz,2H,CH2),3.71(t,J=3.60Hz,4H,CH2),2.94(t,J=3.40Hz,4H,CH2),2.41(s,3H,CH3),1.35(t,J=5.40Hz,3H,CH3).ESI-MS:m/z 411.5(M+).
实施例十一:1-乙基-吲哚-3-甲酰-(4-对氯磺胺)哌嗪(化合物17)的制备
制备方法参考实施例一。黄色固体,产率53%;1H NMR(DMSO-d6,300MHz)δ:8.46(d,J=6.60Hz,2H,ArH,CHN),8.03(d,J=6.80Hz,2H,ArH),7.75(s,1H,ArH),7.64(d,J=5.90Hz,1H,ArH),7.53(d,J=6.30Hz,1H,ArH),7.20(t,J=5.70Hz,1H,ArH),7.10(t,J=5.70Hz,1H,ArH),4.22(q,J=5.40Hz,2H,CH2),3.75(t,J=3.60Hz,4H,CH2),3.07(t,J=3.50Hz,4H,CH2),1.36(t,J=5.30Hz,3H,CH3).ESI-MS:m/z 442.5(M+).
实施例十二:1-乙基-吲哚-3-甲酰-(4-对硝基磺胺)哌嗪(化合物18)的制备
制备方法参考实施例一。白色固体,产率53%;1H NMR(DMSO-d6,300MHz)δ:7.85(s,1H,ArH),7.72(d,J=5.60Hz,1H,CHN),7.54(d,J=6.20Hz,1H,ArH),7.31(s,2H,ArH),7.21(t,J=5.70Hz,1H,ArH),7.13(t,J=5.50Hz,1H,ArH),4.24(q,J=5.30Hz,2H,CH2),4.14~4.07(m,2H,CH),3.70(t,J=3.40Hz,4H,CH2),3.14(t,J=3.50Hz,4H,CH2),2.99~2.89(m,1H,CH),1.38(t,J=5.40Hz,3H),1.22(d,J=6.00Hz,18H,CH3).ESI-MS:m/z 523.7(M+).
实施例十三:1-甲基-吲哚-3-甲酰-(4-对氯磺胺)哌嗪(化合物19)的制备
制备方法参考实施例一。白色固体,产率63%;1H NMR(DMSO-d6,300MHz)δ:7.98(d,J=6.60Hz,1H,ArH),7.83(s,1H,CHN),7.71~7.67(m,4H,ArH),7.56(d,J=5.10Hz,2H,ArH),7.22(t,J=5.40Hz,1H,ArH),7.14(t,J=5.50Hz,1H,ArH),4.17(t,J=5.50Hz,2H,CH2),3.76(t,J=3.80Hz,4H,CH2),3.07(t,J=3.60Hz,4H,CH2),1.87~1.78(m,2H,CH2),0.87(t,J=5.80Hz,3H,CH3).ESI-MS:m/z 412.2(M+).
实施例十四:1-甲基-吲哚-3-甲酰-(4-对甲基磺胺)哌嗪(化合物20)的制备
制备方法参考实施例一。亮黄色固体,产率63%;1H NMR(DMSO-d6,300MHz)δ:7.88(d,J=6.30Hz,2H,ArH,CHN),7.76(s,1H,ArH),7.69~7.64(m,3H,ArH),7.53(d,J=6.10Hz,1H,ArH),7.19(t,J=5.70Hz,1H,ArH),7.10(t,J=5.50Hz,1H,ArH),4.15(t,J=5.30Hz,2H,CH2),3.72(t,J=3.50Hz,4H,CH2),3.00(t,J=3.60Hz,4H,CH2),1.82~1.72(m,2H,CH2),0.83(t,J=5.60Hz,3H,CH3).ESI-MS:m/z490.4(M+).
实施例十五:1-甲基-吲哚-3-甲酰-(4-对硝基磺胺)哌嗪(化合物21)的制备
制备方法参考实施例一。白色固体,产率48%;1H NMR(DMSO-d6,300MHz)δ:7.78~7.72(m,5H,ArH,CHN),7.65(d,J=6.10Hz,1H,ArH),7.53(d,J=6.20Hz,1H,ArH),7.19(t,J=5.80Hz,1H,ArH),7.10(t,J=5.60Hz,1H,ArH),4.15(t,J=5.30Hz,2H,CH2),3.72(t,J=3.60Hz,4H,CH2),3.00(t,J=3.60Hz,4H,CH2),1.81~1.72(m,2H,CH2),0.83(t,J=5.60Hz,3H,CH3).ESI-MS:m/z 445.9(M+).
实施例十六:1-甲基-吲哚-3-甲酰-(4-(2′,4′,5′-三异丙基)对甲基磺胺)哌嗪(化合物22)的制备
制备方法参考实施例一。棕色固体,产率59%;1H NMR(DMSO-d6,300MHz)δ:7.75(s,1H,ArH),7.64(d,J=6.10Hz,3H,ArH,CHN),7.52(d,J=6.10Hz,1H,ArH),7.46(d,J=6.00Hz,2H,ArH),7.18(t,J=5.70Hz,1H,ArH),7.09(t,J=5.70Hz,1H,ArH),4.14(t,J=5.30Hz,2H,CH2),3.71(t,J=3.60Hz,4H,CH2),2.94(t,J=3.30Hz,4H,CH2),2.41(s,3H,CH3),1.81~1.72(m,2H,CH2),0.82(t,J=5.60Hz,3H,CH3).ESI-MS:m/z 425.6(M+).
实施例十七:1-丙基-吲哚-3-甲酰-(4-对氯磺胺)哌嗪(化合物23)的制备
制备方法参考实施例一。黄色固体,产率58%;1H NMR(DMSO-d6,300MHz)δ:8.45(d,J=6.60Hz,2H,ArH,CHN),8.03(d,J=6.60Hz,2H,ArH),7.74(s,1H,ArH),7.64(d,J=6.00Hz,1H,ArH),7.53(d,J=6.10Hz,1H,ArH),7.18(t,J=5.80Hz,1H,ArH),7.09(t,J=5.60Hz,1H,ArH),4.15(t,J=5.30Hz,2H,CH2),3.73(t,J=3.50Hz,4H,CH2),3.07(t,J=3.40Hz,4H,CH2),1.81~1.72(m,2H,CH2),0.82(t,J=5.50Hz,3H,CH3).ESI-MS:m/z 456.5(M+).
实施例十八:1-丙基-吲哚-3-甲酰-(4-对溴磺胺)哌嗪(化合物24)的制备
制备方法参考实施例一。白色固体,产率54%;1H NMR(DMSO-d6,300MHz)δ:7.84(s,1H,ArH),7.71(d,J=5.90Hz,1H,CHN),7.55(d,J=6.20Hz,1H,ArH),7.31(s,2H,ArH),7.20(t,J=5.70Hz,1H,ArH),7.12(t,J=5.60Hz,1H,ArH),4.17(t,J=5.30Hz,2H,CH2),4.13~4.06(m,2H,CH),3.69(t,J=3.50Hz,4H,CH2),3.13(t,J=3.40Hz,4H,CH2),2.98~2.91(m,1H,CH),1.83~1.74(m,2H,CH2),1.22(d,J=5.30Hz,18H,CH3),0.84(t,J=5.60Hz,3H,CH3),.ESI-MS:m/z 537.8(M+).
实施例十九:1-丙基-吲哚-3-甲酰-(4-对硝基磺胺)哌嗪(化合物25)的制备
制备方法参考实施例一。白色固体,产率73%;1H NMR(DMSO-d6,300MHz)δ:8.46(d,J=6.60Hz,2H,ArH,CHN),8.03(d,J=6.80Hz,2H,ArH),7.75(s,1H,ArH),7.64(d,J=5.90Hz,1H,ArH),7.53(d,J=6.30Hz,1H,ArH),7.20(t,J=5.70Hz,1H,ArH),7.10(t,J=5.70Hz,1H,ArH),4.22(q,J=5.40Hz,2H,CH2),3.75(t,J=3.60Hz,4H,CH2),3.07(t,J=3.50Hz,4H,CH2),1.36(t,J=5.30Hz,3H,CH3).ESI-MS:m/z 442.5(M+).
实施例二十:1-丙基-吲哚-3-甲酰-(4-(2′,4′,5′-三异丙基)对甲基磺胺)哌嗪(化合物26)的制备
制备方法参考实施例一。亮黄色固体,产率53.%;1H NMR(DMSO-d6,300MHz)δ:7.94(s,1H,ArH),7.88(q,J=6.40Hz,2H,ArH,CHN),7.70~7.65(m,3H,ArH),7.48(d,J=6.100Hz,1H,ArH),7.33~7.23(m,5H,ArH),7.17~7.08(m,2H,ArH),5.44(s,2H,CH2),3.74(t,J=3.60Hz,4H,CH2),3.01(t,J=3.60Hz,4H,CH2).ESI-MS:m/z 494.0(M+).
实施例二十一:1-苄基-吲哚-3-甲酰-(4-对氯磺胺)哌嗪(化合物27)的制备
制备方法参考实施例一。白色固体,产率52%;1H NMR(DMSO-d6,300MHz)δ:7.92(s,1H,ArH),7.75(q,J=6.40Hz,4H,ArH,CHN),7.66(d,J=5.90Hz,1H,ArH),7.47(d,J=6.100Hz,1H,ArH),7.32~7.23(m,5H,ArH),7.17~7.7(m,2H,ArH),5.44(s,2H,CH2),3.74(t,J=3.40Hz,4H,CH2),3.02(t,J=3.50Hz,4H,CH2).ESI-MS:m/z 494.0(M+).
实施例二十二:1-苄基=吲哚=3-甲酰=(4=(2′,4′,5′-三异丙基)对甲基磺胺)哌嗪(化合物28)的制备
制备方法参考实施例一。黄色固体,产率47%;1H NMR(DMSO-d6,300MHz)δ:8.46(d,J=6.60Hz,2H,ArH,CHN),8.03(d,J=6.80Hz,2H,ArH),7.75(s,1H,ArH),7.64(d,J=5.90Hz,1H,ArH),7.53(d,J=6.30Hz,1H,ArH),7.20(t,J=5.70Hz,1H,ArH),7.10(t,J=5.70Hz,1H,ArH),4.22(q,J=5.40Hz,2H,CH2),3.75(t,J=3.60Hz,4H,CH2),3.07(t,J=3.50Hz,4H,CH2),1.36(t,J=5.30Hz,3H,CH3).ESI-MS:m/z 442.5(M+).
实施例二十三:1-甲基-吲哚-3-甲酰-(4=(2′,4′,5′-三异丙基)对甲基磺胺)哌嗪(化合物29)的制备
制备方法参考实施例一。黄色固体,产率47%;1H NMR(DMSO-d6,300MHz)δ:8.46(d,J=6.50Hz,2H,ArH,CHN),8.03(d,J=6.60Hz,2H,ArH),7.91(s,1H,ArH),7.65(d,J=5.80Hz,1H,ArH),7.48(d,J=5.90Hz,1H,ArH),7.33~7.23(m,5H,ArH),7.17~7.07(m,2H,ArH),5.44(s,2H,CH2),3.75(t,J=3.60Hz,4H,CH2),3.09(t,J=3.50Hz,4H,CH2).ESI-MS:m/z 504.6(M+).
实施例二十四:1-苄基-吲哚-3-甲酰-(4-对硝基磺胺)哌嗪(化合物30)的制备
制备方法参考实施例一。白色固体,产率64%;1H NMR(DMSO-d6,300MHz)δ:8.02(s,1H,ArH),7.72(q,J=5.90Hz,1H,CHN),7.49(d,J=5.90Hz,1H,ArH),7.33~7.24(m,7H,ArH),7.18~7.09(m,2H,ArH),5.45(s,2H,CH2),4.14~4.07(m,2H,CH),3.70(t,J=3.20Hz,4H,CH2),3.15(t,J=3.50Hz,4H,CH2),2.98~2.91(m,1H,CH),1.22(d,J=3.20Hz,18H,CH3).ESI-MS:m/z 585.8(M+).
实施例二十五:
化合物25的体外抗肿瘤活性关于抗肿瘤细胞增殖的研究
采用MTT[3-(4,5)-双甲基-2-噻唑-(2,5)-苯基溴化四氮唑蓝]法来测定化合物25对***细胞(HeLa)的半数抑制浓度(IC50)。
(1)培养液(/L)的配制:①悬浮细胞:DMEM培养粉一袋(10.4g),新生牛血清100mL,青霉素溶液(2×10-5U/mL)0.5mL,链霉素溶液(2×10-5U/mL)0.5mL,加三蒸水溶解后,用5.6%的NaHCO3溶液调pH值至7.2-7.4,最后定容至1000mL。过滤灭菌。②贴壁细胞:同上,再加入NaHCO32.00g,HEPES 2.38g。
(2)D-Hanks缓冲液(每升)的配制:NaCl 8.00g,KCl 0.40g,Na2HPO4·12H2O0.06g,KH2PO40.06g,NaHCO30.35g。高压灭菌。
(3)胰蛋白酶液的配制:利用D-Hanks缓冲液配成浓度为0.5%胰蛋白酶液。过滤除菌。
(4)实验药液的配制:将测试样品用少量的三蒸水溶解配成储备液,即按实验最高浓度的10倍配制储备液。根据化合物溶解性不同,可用三蒸水直接溶解,或用少量DMSO助溶,再加三蒸水溶解。储备液保存于-20℃冰箱中备用。
(5)***细胞(HeLa)的培养:为贴壁生长细胞,常规培养于DMEM培养液内(含10%小牛血清、100U/mL链霉素),置于37℃、5%CO2培养箱中培养,每隔3-4d传代一次。传代时将原瓶中培养液转移至离心管中,1000rpm离心5min,弃去原培养液,加入等量新鲜培养液,吹打均匀,移取适量至新鲜培养瓶中,再补充新鲜培养液至原体积(培养液体积约为培养瓶容量的1/10)。
(6)细胞孵育:取对数生长期的肿瘤细胞,调细胞悬液浓度为1-1.5×105个/mL。在96孔培养板中每孔加细胞悬液100μL,置37℃,5%CO2培养箱中培养24h。培养24h后,分别按设计加入药液。
(7)加药:将测试药液按照最终浓度的浓度梯度分别加入到各个孔中,每个浓度设6个平行孔。实验分为药物试验组(分别加入不同浓度的测试药)、对照组(只加培养液和细胞,不加测试药)和空白组(只加培养液,不加细胞和测试药)。将加药后的96孔板置于37℃,5%CO2培养箱中培养48h。阳性对照药物的活性按照测试样品的方法测定。
(8)存活细胞的测定:在培养了48h后的96孔板中,每孔加MTT 40μL(用D-Hanks缓冲液配成4mg/mL)。在37℃放置4h后,移去上清液。每孔加150μLDMSO,振荡5min,使formazan结晶溶解。最后,利用自动酶标仪在490nm波长处检测各孔的光密度(OD值)。
半数抑制浓度(IC50)定义为当50%的肿瘤细胞存活时的药物浓度。根据测定的光密度(OD值),制作细胞生长抑制率的标准曲线,在标准曲线上求得其对应的药物浓度。
测得化合物25的IC50值为6.0μM。
从上述实验可知:本发明的含吲哚=3羧酸骨架的哌嗪类衍生物25对***细胞(HeLa)有明显的抑制作用。因此,本发明的含吲哚=3羧酸骨架的哌嗪类衍生物可以应用于制备抗肿瘤药物。
以上详细描述了本发明的优选实施方式,但是,本发明并不限于上述实施方式中的具体细节,在本发明的技术构思范围内,可以对本发明的技术方案进行多种等同变换,这些等同变换均属于本发明的保护范围。另外需要说明的是,在上述具体实施方式中所描述的各个具体技术特征,在不矛盾的情况下,可以通过任何合适的方式进行组合。为了避免不必要的重复,本发明对各种可能的组合方式不再另行说明。此外,本发明的各种不同的实施方式之间也可以进行任意组合,只要其不违背本发明的思想,其同样应当视为本发明所公开的内容。
Claims (3)
1.一类含吲哚-3羧酸骨架的哌嗪类衍生物,其具有如下所示的结构,
其中,所述R1选自烷基、芳香基等;R2选自烷基、芳香基、卤素等。
2.一种制备含吲哚-3羧酸骨架的哌嗪类衍生物的方法,其特征在于,所述含吲哚-3羧酸骨架的哌嗪类衍生物具有如式下所示的结构,
其中,所述R1选自烷基、芳香基等;R2选自烷基、芳香基、卤素等。
其合成过程,有如下通式:
所述方法包括如下步骤:
步骤1:在0±5℃搅拌作用下,将化合物1溶于无水甲醇中,并滴加SOCl2,转移至80±10℃,搅拌反应,制得中间体化合物2;各物质的摩尔比为I∶SOCl3=1∶2~5,反应时间为6±3h;进一步优选的摩尔比为1∶4,优选的温度分别为0℃、80℃,优选的反应时间8h;
步骤2:在0±5℃搅拌作用下,依次向反应容器中加入溶有中间体化合物2的THF溶液,然后缓慢滴加溶有少量NaH的THF溶液,移至室温后慢慢滴加卤代烃。继续搅拌反应12h,减压除去THF,乙酸乙酯萃取,有机层依次用饱和的食盐水和蒸馏水洗涤,无水硫酸镁干燥,减压除去溶剂得粗产物3.
步骤3:在0±5℃搅拌作用下,依次向反应容器中加入化合物3、氢氧化钾溶液,THF,甲醇,水,70±5℃搅拌;反应结束后酸化得中间体4。
步骤4:在搅拌作用下,依次向反应容器中加入磺酰氯、哌嗪、DMAP和二氯甲烷,室温反应中间体6e-6j。
步骤5:在0±5℃搅拌作用下,依次向反应容器中加入4a-4d、6e-6j、DMAP、HOBT、无水二氯甲烷和EDC.HCl,转移至25±10℃继续搅拌反应,提取得到目标化合物7-31。
3.一种具有如下所示的结构的含吲哚-3羧酸骨架的哌嗪类衍生物在制备抗肿瘤药物中的应用,
其中,所述R1选自烷基、芳香基等;R2选自烷基、芳香基、卤素等。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510252697.6A CN104876851A (zh) | 2015-05-15 | 2015-05-15 | 一类含吲哚-3羧酸骨架的哌嗪类衍生物的制备方法及在抗癌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510252697.6A CN104876851A (zh) | 2015-05-15 | 2015-05-15 | 一类含吲哚-3羧酸骨架的哌嗪类衍生物的制备方法及在抗癌药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104876851A true CN104876851A (zh) | 2015-09-02 |
Family
ID=53944570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510252697.6A Pending CN104876851A (zh) | 2015-05-15 | 2015-05-15 | 一类含吲哚-3羧酸骨架的哌嗪类衍生物的制备方法及在抗癌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104876851A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060172971A1 (en) * | 2001-10-22 | 2006-08-03 | Thomas Nicotera | Protection against and treatment of hearing loss |
CN1826319A (zh) * | 2003-07-24 | 2006-08-30 | 安万特医药股份有限公司 | 芳基杂芳族化合物、含有它们的组合物及其用途 |
CN1870991A (zh) * | 2003-09-04 | 2006-11-29 | 安万特药物公司 | 作为多聚(adp-核糖)聚合酶(parp)抑制剂的被取代的吲哚类化合物 |
CN101195601A (zh) * | 2006-12-04 | 2008-06-11 | 江苏先声药物研究有限公司 | 2-二氢吲哚酮衍生物及其制备方法和用途 |
CN102015639A (zh) * | 2008-05-07 | 2011-04-13 | 医学研究委员会 | 用于稳定p53突变体的化合物 |
CN102702068A (zh) * | 2007-12-03 | 2012-10-03 | 江苏先声药物研究有限公司 | 3-吡咯并环己亚基-2-二氢吲哚酮衍生物及其用途 |
CN102952062A (zh) * | 2011-08-12 | 2013-03-06 | 中国医学科学院医药生物技术研究所 | 取代苯并杂环类化合物及其制备方法和应用 |
WO2014146494A1 (zh) * | 2013-03-20 | 2014-09-25 | 中国科学院上海药物研究所 | β-氨基羰基类化合物、其制备方法、药物组合物及其用途 |
-
2015
- 2015-05-15 CN CN201510252697.6A patent/CN104876851A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060172971A1 (en) * | 2001-10-22 | 2006-08-03 | Thomas Nicotera | Protection against and treatment of hearing loss |
CN1826319A (zh) * | 2003-07-24 | 2006-08-30 | 安万特医药股份有限公司 | 芳基杂芳族化合物、含有它们的组合物及其用途 |
CN1870991A (zh) * | 2003-09-04 | 2006-11-29 | 安万特药物公司 | 作为多聚(adp-核糖)聚合酶(parp)抑制剂的被取代的吲哚类化合物 |
CN101195601A (zh) * | 2006-12-04 | 2008-06-11 | 江苏先声药物研究有限公司 | 2-二氢吲哚酮衍生物及其制备方法和用途 |
CN102702068A (zh) * | 2007-12-03 | 2012-10-03 | 江苏先声药物研究有限公司 | 3-吡咯并环己亚基-2-二氢吲哚酮衍生物及其用途 |
CN102015639A (zh) * | 2008-05-07 | 2011-04-13 | 医学研究委员会 | 用于稳定p53突变体的化合物 |
CN102952062A (zh) * | 2011-08-12 | 2013-03-06 | 中国医学科学院医药生物技术研究所 | 取代苯并杂环类化合物及其制备方法和应用 |
WO2014146494A1 (zh) * | 2013-03-20 | 2014-09-25 | 中国科学院上海药物研究所 | β-氨基羰基类化合物、其制备方法、药物组合物及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104558093B (zh) | C21甾体皂苷苷元衍生物、其制备方法及其在制备抗肿瘤药物中的应用 | |
CN104530021A (zh) | 化合物、其制备方法、其在制备抗肿瘤药物中的应用及其制备的抗肿瘤药物 | |
CN104558094A (zh) | 皂苷苷元衍生物、其制备方法及在制备抗肿瘤药物中的应用 | |
CN102911118B (zh) | 一类苯并氮杂卓类衍生物及其制备方法和用途 | |
CN103864765B (zh) | 含有五元杂环的苯并氮杂卓类衍生物、其制备方法和用途 | |
CN102675205B (zh) | 一种吡唑肟醚类化合物及其制备与在抗癌治疗中的应用 | |
CN104876851A (zh) | 一类含吲哚-3羧酸骨架的哌嗪类衍生物的制备方法及在抗癌药物中的应用 | |
CN104292211A (zh) | 地氯雷他定类一氧化氮供体及其制备方法和用途 | |
CN103588758A (zh) | 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用 | |
CN104829534A (zh) | 一类含萘环骨架的二氢吡唑吗啉衍生物的制备方法及在抗癌药物中的应用 | |
CN107739381A (zh) | 莪术醇衍生物及其在制备抗肿瘤药物中的应用 | |
CN105037265A (zh) | 一类含查尔酮骨架的喹啉酮衍生物的制备方法及在抗癌药物中的应用 | |
CN105523961B (zh) | 一类含肉桂酰腙骨架的多甲氧基的抗肿瘤化合物的设计、合成及生物活性评价 | |
CN102485735B (zh) | 6-果糖氨-4-芳胺基喹唑啉衍生物及其用途 | |
CN104926804A (zh) | 一类具有抗肿瘤作用的化合物、其制备方法和用途 | |
CN104961683A (zh) | 一类含萘环骨架的二氢吡唑哌嗪衍生物的制备方法及在抗癌药物中的应用 | |
CN104529905B (zh) | N‑3‑苯并咪唑酰双胺类衍生物及其制备方法与应用 | |
CN104230786B (zh) | 一种具有抗肿瘤活性的含吲哚结构的化合物及其合成方法 | |
CN104861026A (zh) | 含呋喃骨架的二氢吡唑氧肟酸c21甾体皂苷苷元衍生物、其制备方法及应用 | |
CN104804066A (zh) | 新型抗癌化合物、其制备方法以及制备抗癌药物的用途 | |
CN104804064A (zh) | 含萘环骨架的二氢吡唑氧肟酸c21甾体皂苷苷元衍生物及其制备方法与应用 | |
CN107698511B (zh) | 一种1,3-二芳基-5-烷氧基吡唑化合物及其制备方法和应用 | |
CN104877002A (zh) | 一种二氢吡唑哌嗪c21甾体皂苷苷元衍生物,及其制备方法与应用 | |
CN105061440A (zh) | 含乙酰氨基氮杂环的香豆素并吡唑类化合物及其制备与在抑制肿瘤细胞中的应用 | |
CN104788530B (zh) | 含苯并二噁烷骨架的皂苷苷元衍生物、其制备方法及在制备抗肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150902 |